2023-04-17 21:05:00
(Seoul=News 1) Bio-specialist Jae-joon Seong = Tigiana Life Sciences, a British bio company specializing in antibodies, announced that it would develop a treatment for long-term Covid (long-term sequelae of the corona) that is rooted in the nasal cavity (nasal cavity).
The company was developing the candidate as a treatment for the new coronavirus infection (Corona 19). However, as the Corona 19 epidemic eased, it seems that the application target was changed to Long Covid.
According to the industry on the 18th, Tiziana announced that it is developing an intranasal antibody ‘Poralumab’ for the treatment of long Covid. According to Tijaana, poralumab inactivates microglia, a key factor in the pathogenesis of Long Covid. Microglial cells are cells that carry out immune activities in the brain.
The World Health Organization (WHO) defines long-COVID patients as patients who continue to show symptoms for at least two months following infection with Corona 19. It can cause various complications, and regarding 10 to 20% of all COVID-19 infections belong to this category. According to Tigiana, the cost borne by the medical system for long Covid treatment in the United States is regarding $ 2.6 trillion (approximately 3412.5 trillion won).
Foralumab is an anti-CD3 human monoclonal antibody (mAb) that binds to the T-cell receptor, an immune cell, and modulates cell function to reduce lung inflammation. Through this, it suppresses the cytokine storm, an excessive inflammatory response in lower immune cells, and improves respiratory failure in patients.
Prior to COVID-19, clinical trials were underway for multiple sclerosis or non-alcoholic steatohepatitis (NASH) as an oral (eating) drug. Since then, in 2020, at the beginning of the COVID-19 epidemic, Tiziana has been developing it as a COVID-19 treatment while confirming the effect in phase 1 clinical trials, which were developed as a formulation to be sprayed into the nasal cavity.
Matthew Davis, chief medical officer of Tigiana, said, “We expect to enter phase 2a placebo-controlled clinical trials following receiving successful feedback from the US Food and Drug Administration (FDA).”
“Using a PET scan, we can determine whether intranasal poralumab reduces activated microglia in patients with Long Covid 3 months following administration. We plan to submit an application for clinical trial approval (IND).”
Separately, Tiziana plans to start a phase 2 clinical trial of poralumab in patients with inactive secondary progressive multiple sclerosis (SPMS) during the third quarter of this year.
Meanwhile, as the scale of the Corona 19 epidemic decreases, other Corona 19 treatments are also expanding their indications to Long Covid.
US Pfizer is conducting a clinical trial using the Corona 19 treatment ‘Paxrovid’ (ingredients Nirmatrelvir and Ritonavir), which is eaten for the treatment of Long Covid. There have been reports that Paxrovid has improved the symptoms of corona sequelae before, but it is trying to prove its effectiveness through proper clinical trials.
Recently, Japan’s Shionogi Pharmaceutical announced the results of a clinical trial related to the sequelae of Corona 19 for its Corona 19 treatment ‘Zokoba’ (ingredient Encitrelvir fumaric acid). After 6 months of taking Zokova, it succeeded in reducing the proportion of patients who confirmed at least twice among 14 major symptoms, such as cough and sore throat, by 45% compared to placebo.
In Korea, Hyundai Bioscience announced in November of last year that it would administer its COVID-19 treatment candidate ‘CP-COV03’ to 40 patients with long Covid-19 and enter a clinical trial by researchers to confirm its safety and effectiveness.
1681766895
#Roots #candidate #corona #treatment #applied #long #Covid #treatment
